• Medicine
  • Published in
    The Journal of clinical and…
    2011

Randomized Controlled Trial of Desonlde Hydrogel 0.05% versus Desonide Ointment 0.05% in the Treatment of Mild-to-moderate Atopic Dermatitis.

@article{Trookman2011RandomizedCT,
  title={Randomized Controlled Trial of Desonlde Hydrogel 0.05% versus Desonide Ointment 0.05% in the Treatment of Mild-to-moderate Atopic Dermatitis.},
  author={Nathan S. Trookman and Ronald L. Rizer},
  journal={The Journal of clinical and aesthetic dermatology},
  year={2011},
  volume={4 11},
  pages={
          34-8
        }
}
OBJECTIVE Desonide hydrogel 0.05%, an effective treatment for mild-to-moderate atopic dermatitis, is United States Food and Drug Administration approved as a treatment for patients as young as three months of age. Previous studies have also demonstrated that this hydrogel formulation of desonide 0.05% improved moisturization and reduced transepidermal water loss. Increased skin hydration has been correlated with improved and sustained integrity of the epidermal barrier in patients with atopic… CONTINUE READING